Reconstituted HDL for Diabetic Endothelial Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Diabetic patients with type 2 diabetes mellitus suffer from endothelial dysfunction, which is a hallmark of their condition and predictive of future cardiovascular events, and existing therapies like statins do not fully normalize vascular dysfunction despite intensive treatment.
Innovation Solution
Administration of reconstituted high-density lipoprotein (rHDL) to improve endothelial function by increasing apoA-I levels and enhancing nitric oxide synthase activity, thereby improving endothelium-dependent vasodilation and reducing cardiovascular risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If statin therapy is used to treat endothelial dysfunction in diabetic patients, then cardiovascular events are reduced, but endothelial function is not fully normalized
Solution Approach 1:
The patent introduces HDL (high-density lipoprotein) as an intermediary substance that mediates between statin therapy and endothelial function restoration. HDL acts as a carrier that transports cholesterol and activates endothelial nitric oxide synthase, providing an additional mechanism beyond statins to improve endothelial function in diabetic patients.
Solution Approach 2:
The patent focuses on changing the HDL parameter (increasing HDL levels and improving HDL function) to achieve better endothelial function. By modifying HDL-related parameters rather than relying solely on statin therapy, the patent aims to normalize endothelial function while maintaining cardiovascular event reduction.
2Reliability
If intensive statin treatment is applied to DM2 patients, then cardiovascular protection is enhanced, but vascular dysfunction persists
Solution Approach 1:
HDL serves as a complementary intermediary that works alongside statins to address persistent vascular dysfunction. The patent positions HDL as an additional therapeutic agent that can restore endothelial function without interfering with statin-induced cardiovascular protection.
Solution Approach 2:
The patent merges statin therapy with HDL supplementation or enhancement strategies. This combination approach allows patients to benefit from both the cardiovascular protection provided by statins and the endothelial function restoration provided by HDL, addressing both protective and harmful aspects simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
rHDL infusion significantly improves endothelial function in diabetic patients, with effects persisting for at least 7 days post-treatment, even when HDL levels return to baseline, offering a potential therapeutic benefit beyond traditional statin therapy.
Implementation Method 1
HDLs can also activate endothelial nitric oxide (NO) synthase subsequent to its interaction with scavenger receptor-B 1 (SR-B1)
Implementation Method 2
The mechanism/mechanisms via which HDLs provide these cardioprotective actions are not clearly understood, but may include a role for HDLs in reverse transport of cholesterol from peripheral tissues to the liver
Implementation Method 3
inhibition of the oxidation of low-density lipoproteins
Implementation Method 4
modulation of vasodilatation and platelet activation mediated by changes in the production of prostacyclin
Data Source
AI summary
A method for the treatment of endothelial dysfunction in a diabetic patient, including both diabetes induced macrovascular disorders and diabetes induced microvascular disorders, comprises administration, preferably parenteral administration, to the patient of an effective amount of high density lipoprotein (HDL).